The tweet was deleted by the author.
But we saved everything 🙂.
Humacyte presented new long term clinical data for its ATEV vessel at the 2026 ISVTE-ISACB Joint Meeting in Miami.
The analysis covered ATEVs from 52 patients enrolled across five clinical trials, providing important insight into the vessel's low susceptibility to atherosclerosis over time.
View post on X Loading...
Humacyte previously presented interim Phase 3 results for its ATEV vessel in women requiring hemodialysis access at Kidney Week. The company has also shared new clinical data on its bioengineered human vessels at VEITHsymposium. These earlier updates focused on advances in tissue engineered vascular grafts.